{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:04:01Z","timestamp":1765994641534,"version":"3.41.2"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01010","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T16:53:35Z","timestamp":1573836815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country"],"prefix":"10.3389","volume":"10","author":[{"given":"Edward","family":"Mezones-Holguin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio Violeta","family":"Gamboa-Cardenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gadwyn","family":"Sanchez-Felix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ch\u00e1vez-Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Miguel","family":"Helguero-Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Max","family":"Laban Seminario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Alejandra","family":"Burela-Prado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel Marilu","family":"Castro-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Fiestas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"volume-title":"Infliximab: Pharmacology, Uses and Limitations","year":"2012","author":"Acevedo","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/bjd.14788","article-title":"A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis","volume":"176","author":"Ali","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"The Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tibtech.2018.06.001","article-title":"Regulatory Convergence for biologics through capacity building and training","volume":"37","author":"Auclair","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15280","article-title":"The burden of common skin diseases assessed with the EQ5DTM: a European multicentre study in 13 countries","volume":"176","author":"Balieva","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1586\/17474124.2015.1091307","article-title":"The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications","volume":"9","author":"Ben-Horin","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1590\/S1726-46342011000300019","article-title":"Synthesis studies as the basis for economic evaluations in health: the need for their quality appraisal","volume":"28","author":"Bola\u00f1os-D\u00edaz","year":"2011","journal-title":"Rev. Peru. Med. Exp. Salud P\u00fablica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/ard.2006.060384","article-title":"How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis","volume":"66","author":"Boonen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/1740774518795637","article-title":"Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials","volume":"15","author":"Bottomley","year":"2018","journal-title":"Clin. Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fphar.2018.00794","article-title":"Quality of life and cost study of rheumatoid arthritis therapy With biological medicines","volume":"9","author":"Boyadzieva","year":"2018","journal-title":"Front. Pharmacol."},{"volume-title":"Measuring and valuing health benefits for economic evaluation","year":"2017","author":"Brazier","key":"B11"},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses","volume":"57","author":"Brookes","year":"2004","journal-title":"J. Clin. Epidemiol."},{"volume-title":"The measurement and valuation of health status using EQ-5D: A European Perspective: Evidence from the EuroQol BIOMED Research Programme","year":"2013","author":"Brooks","key":"B13"},{"key":"B14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.7326\/M16-0428","article-title":"Bioequivalence of biosimilar tumor necrosis factor-\u03b1 inhibitors compared with their reference biologics: a systematic review","volume":"165","author":"Chingcuanco","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","article-title":"Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes","volume":"78","author":"Cohen","year":"2018","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pupt.2018.09.009","article-title":"Building reliable evidence from real-world data: needs, methods, cautiousness and recommendations","volume":"53","author":"Corrao","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","article-title":"Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement","volume":"16","author":"Dakin","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"B18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","article-title":"The language of biosimilars: clarification, definitions, and regulatory aspects","volume":"77","author":"Declerck","year":"2017","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"B20","first-page":"681","article-title":"Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression","volume":"35","author":"Druyts","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"mAbs"},{"article-title":"Remicade (Infliximab)","volume-title":"Eur. Med. Agency","year":"2018","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","article-title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","volume":"49","author":"Feagan","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"year":"2018","key":"B24","article-title":"Remicade (infliximab)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.phrs.2018.01.024","article-title":"Biosimilars: Concepts and controversies","volume":"133","author":"Gamez-Belmonte","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-016-0564-1","article-title":"The regulation of biosimilars in Latin America","volume":"18","author":"Garcia","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jval.2017.08.3012","article-title":"Making real-world evidence more useful for decision making","volume":"20","author":"Greenfield","year":"2017","journal-title":"Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-99680-6","volume-title":"Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development","author":"Gutka","year":"2018"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.semarthrit.2018.03.006","article-title":"The use of routinely collected patient-reported outcome measures in rheumatoid arthritis","volume":"48","author":"Hiligsmann","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","article-title":"Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction","volume":"41","author":"Ingrasciotta","year":"2018","journal-title":"Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"The Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","article-title":"Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent","volume":"32","author":"Kristensen","year":"2018","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"B35","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","volume-title":"Cochrane Database Syst. Rev.","author":"LeBlanc","year":"2015"},{"key":"B36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-017-0256-z","article-title":"Biosimilarity and interchangeability: principles and evidence: a systematic review","volume":"32","author":"McKinnon","year":"2018","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"196","DOI":"10.17843\/rpmesp.2019.362.3998","article-title":"[Health insurance coverage: the peruvian case since the universal insurance act]","volume":"36","author":"Mezones-Holguin","year":"2019","journal-title":"Rev. Peru. Med. Exp. Salud Publica"},{"year":"2016","key":"B42","article-title":"Reglamento que regula la presentaci\u00f3n y contenido de los documentos requeridos en la inscripci\u00f3n y reinscripci\u00f3n de productos biol\u00f3gicos que opten por la v\u00eda de la similaridad"},{"key":"B43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14737167.2016.1200468","article-title":"Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis","volume":"17","author":"Mlcoch","year":"2017","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1201\/b19161","volume-title":"Biosimilars and Interchangeable Biologics: Strategic Elements","author":"Niazi","year":"2018"},{"key":"B46","doi-asserted-by":"publisher","first-page":"952","DOI":"10.18553\/jmcp.2018.24.10.952","article-title":"The biosimilar nocebo effect? a systematic review of double-blinded versus open-label studies","volume":"24","author":"Odinet","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.biologicals.2009.07.003","article-title":"Review of regulation of biological and biotechnological products in Latin American and Caribbean countries","volume":"37","author":"Pombo","year":"2009","journal-title":"Biol. J. Int. Assoc. Biol. Stand."},{"key":"B49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14712598.2017.1330409","article-title":"Biologicals and biosimilars: safety issues in Europe","volume":"17","author":"Portela","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/apt.15223","article-title":"Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients","volume":"49","author":"Pouillon","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fpubh.2015.00164","article-title":"Economic evaluation enhances public health decision making","volume":"3","author":"Rabarison","year":"2015","journal-title":"Front. Public Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"NP2372","DOI":"10.1177\/1010539511432879","article-title":"The Spanish SF-36 in Peru: factor structure, construct validity, and internal consistency","volume":"27","author":"Salazar","year":"2015","journal-title":"Asia. Pac. J. Public Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.17843\/rpmesp.2014.314.129","article-title":"El sistema nacional de salud en el Per\u00fa","volume":"31","author":"S\u00e1nchez-Moreno","year":"2014","journal-title":"Rev. Peru. Med. Exp. Salud Publica"},{"key":"B54","unstructured":"Petitorio Farmacol\u00f3gico EsSalud2017"},{"volume-title":"Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines","year":"2017","author":"Sheets","key":"B55"},{"key":"B56","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1573397113666170517160726","article-title":"Relationship between rheumatoid arthritis disease activity assessed with the US7 score and quality of Life measured with questionnaires (HAQ, EQ-5D, WPAI)","volume":"13","author":"Skacelova","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1007\/1-4020-5511-0","volume-title":"EQ-5D Value Sets: Inventory, Comparative Review and User Guide","author":"Szende","year":"2007"},{"key":"B59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","article-title":"Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod. Rheumatol."},{"volume-title":"Adverse Events with Biomedicines: Prevention Through Understanding","year":"2013","author":"Tridente","key":"B60"},{"key":"B61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14712598.2018.1410134","article-title":"Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence","volume":"18","author":"Trifir\u00f2","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-017-0677-1","article-title":"Update on biosimilars in asia","volume":"19","author":"Tsai","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","article-title":"Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons","volume":"56","author":"Uhlig","year":"2017","journal-title":"Rheumatol. Oxf. Engl."},{"volume-title":"Biological Drug Products: Development and Strategies","year":"2013","author":"Wang","key":"B64"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s11136-016-1345-z","article-title":"The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis","volume":"25","author":"Yang","year":"2016","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"B66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11136-017-1690-6","article-title":"Psychometric validation of the SF-36\u00ae health survey in ulcerative colitis: results from a systematic literature review","volume":"27","author":"Yarlas","year":"2018","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"B67","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ecco-jcc\/jjy024","article-title":"Burden of ulcerative colitis on functioning and well-being: a systematic literature review of the SF-36\u00ae health survey","volume":"12","author":"Yarlas","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"volume-title":"International Pharmaceutical Law and Practice","year":"2017","author":"Zahl","key":"B69"},{"key":"B70","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/nchem.2629","article-title":"Materials and methods for delivery of biological drugs","volume":"8","author":"Zelikin","year":"2016","journal-title":"Nat. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T01:15:44Z","timestamp":1722042944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":70,"alternative-id":["10.3389\/fphar.2019.01010"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01010","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"article-number":"1010"}}